This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
Icon PLC (ICLR) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.63% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Icon PLC (ICLR) Maintain Its Recent Price Strength
by Zacks Equity Research
Icon PLC (ICLR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Why Icon PLC (ICLR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Why Growth Investors Shouldn't Overlook Icon PLC (ICLR)
by Zacks Equity Research
Icon PLC (ICLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Icon PLC (ICLR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ICLR vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Here's Why Icon PLC (ICLR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Icon PLC (ICLR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Icon PLC (ICLR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Icon PLC (ICLR) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
Why Icon PLC (ICLR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Icon PLC (ICLR) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Icon PLC (ICLR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Philips' (PHG) Diagnosis & Treatment Segment Drives Growth
by Zacks Equity Research
Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.
Philips (PHG) Aids Image-Guided Treatment With New Stent System
by Zacks Equity Research
Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.
ICON (ICRL) Gains From Strategic Acquisitions, Innovation
by Zacks Equity Research
In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Icon PLC (ICLR) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.
Icon PLC (ICLR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Icon PLC (ICLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Icon PLC (ICLR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Icon PLC (ICLR) Soars 4.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.